BIIB

Biogen Inc. (BIIB) Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Biogen Inc. is a global biopharmaceutical company focused on neurology, specialized immunology, and rare diseases. The quarter was defined by the completion of the Apellis Pharmaceuticals acquisition on May 14, 2026, adding the products SYFOVRE and EMPAVELI to the portfolio. The company operates as a single segment and is a large accelerated filer.

Key Financial Metrics

Note: Net income and EPS declined significantly year-over-year due to substantial restructuring charges, acquisition-related expenses, and increased amortization.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 3.4% QoQ and 2.7% YTD, driven by the inclusion of Apellis products (SYFOVRE and EMPAVELI) and growth in Rare Disease (SKYCLARYS, SPINRAZA) and Alzheimer's collaboration (LEQEMBI) revenue.
• MS Portfolio Decline: Multiple Sclerosis revenue decreased 13.0% in Q2 and 6.8% YTD, primarily due to generic competition for TECFIDERA and biosimilar competition for TYSABRI.
• Expense Surge: Total cost and expense increased 36.9% in Q2. Key drivers included:
  • Restructuring Charges: $165.4 million in Q2 (vs. negligible in 2025), primarily for Apellis integration and the "Fit for Growth" program.
  • Acquired IPR&D: $164.0 million in Q2, driven by a $100 million upfront payment to TJ Bio for felzartamab rights.
  • Amortization: Increased due to fair value step-up adjustments on acquired inventory (SKYCLARYS, SYFOVRE, EMPAVELI).
• Liquidity Impact: Cash and marketable securities decreased from $4.2 billion (Dec 2025) to $1.3 billion (June 2026) due to the $5.3 billion Apellis acquisition, partially funded by a new $2.0 billion term loan.

Guidance, Outlook, and Risks

• Acquisition Integration: Management expects the Apellis acquisition to enhance short- and long-term revenue growth. Integration costs are expected to continue as the company realizes synergies.
• Pipeline Updates:
  • Discontinued: BIIB122 (Parkinson's) development discontinued after Phase 2b failure.
  • Advancements: LEQEMBI subcutaneous autoinjector approved; SPINRAZA high-dose regimen approved; Litifilimab granted Breakthrough Therapy designation for CLE.
• Regulatory & Pricing Risks: Significant uncertainty remains regarding the Inflation Reduction Act (IRA) Medicare Part D redesign and potential Most-Favored-Nation (MFN) pricing policies. The company noted a modest unfavorable impact of $90 million to 2025 revenue from IRA provisions.
• Trade & Geopolitics: The company is monitoring new U.S. tariffs on pharmaceuticals and geopolitical tensions (Russia/Ukraine, Middle East) that could impact supply chains and costs.
• Legal Proceedings: Ongoing litigation includes securities actions, patent disputes (IMRALDI, TECFIDERA), and antitrust claims. A judgment of ~$124 million was entered against Biogen in a Genentech royalty dispute, which is currently under appeal.

Investor Verification Checklist

• Apellis Integration Costs: Verify the timeline for realizing synergies and the total expected cost of the restructuring program initiated post-acquisition.
• TECFIDERA Decline Trajectory: Assess the remaining revenue runway for TECFIDERA given the acceleration of generic entrants in the EU and North America.
• Debt Service Capacity: Review the impact of the new $2.0 billion term loan and increased interest expense on future free cash flow, especially as Royalty Pharma funding for litifilimab concludes.
• Inventory Amortization: Confirm the duration and magnitude of non-cash amortization charges related to the fair value step-up of acquired inventory (SKYCLARYS, SYFOVRE, EMPAVELI).
• LEQEMBI Commercialization: Monitor Eisai's execution on the LEQEMBI subcutaneous launch and reimbursement status in key international markets.